Volume | 25,945 |
|
|||||
News | - | ||||||
Day High | 5.38 | Low High |
|||||
Day Low | 5.02 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Windtree Therapeutics Inc | WINT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
5.38 | 5.02 | 5.38 | 5.065 | 5.30 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,834 | 25,945 | US$ 5.20 | US$ 135,020 | - | 4.7772 - 35.10 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:39 | 1 | US$ 4.98 | USD |
Windtree Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
26.05M | 5.15M | - | 0 | -20.29M | -3.94 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Windtree Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical WINT Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.38 | 5.90 | 4.83 | 5.39 | 43,516 | -0.38 | -7.06% |
1 Month | 6.642 | 8.6958 | 4.7772 | 6.67 | 260,894 | -1.64 | -24.72% |
3 Months | 6.6762 | 8.6958 | 4.7772 | 6.58 | 155,990 | -1.68 | -25.11% |
6 Months | 18.54 | 22.3614 | 4.7772 | 9.42 | 213,941 | -13.54 | -73.03% |
1 Year | 27.36 | 35.10 | 4.7772 | 18.76 | 237,807 | -22.36 | -81.73% |
3 Years | 2,016.00 | 3,060.00 | 4.7772 | 900.30 | 1,019,028 | -2,011.00 | -99.75% |
5 Years | 6,255.00 | 9,054.00 | 4.7772 | 993.60 | 806,864 | -6,250.00 | -99.92% |
Windtree Therapeutics Description
Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products. |